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Current sample handling methods for measurement of platinum-DNA
adducts in leucocytes in man lead to discrepant results in DNA adduct
levels and DNA repair
J Mal, J Verweij', ASTh Planting', M de Boer-Dennert', HE van Ingen', MEL van der Burg',
G Stoterl and JHM Schellens'
Laboratory ofExperimental Chemother-apv and Pharmacology, Department of'Medical Oncology, and 'Department ofClinical
Chemistry, Rotterdam Cancer Institute, Dr Daniel den Hoed Kliniek, PO Box 5201, 3008 AE Rotterdam, The Netherlands.
Su_manr DNA adduct levels were measured with atomic spectroscopy in white blood cells (WBCs) from
patients with sold tumours who were treated with six weekly courses of cisplatin. In 21 patients (I) the WBCs
were collected after thawing frozen whole-blood samples according to a previously described method. In 32
other patients (II) WBCs were collected immediately after blood sample collection. The two methods for WBC
collection were also compared in vitro. The maximal DNA adduct levels in vivo after the first course were in I
2.48 ± 1.14 and in 11 1.28 ± 0.40 pg of platinum per fig of DNA (P<0.0001). The DNA 'repair' in the first
course (DNA adduct level at the end of the infusion minus the level 15 h post infusion) was in I 40% ± 29%
and in 11 18% ± 29% (P = 0.009). These differences were consistent in all measured courses. In vitro, the DNA
adduct levels in the freshly prepared WBCs were significantly lower at 0. 1 and 4. but not 24 h, after start of
the incubation with cisplatin than in the WBCs collected after freezing and thawing the blood sample. The
same experiment with carboplatin in vitro also resulted in significantly lower adducts in freshly isolated WBCs.
The higher DNA adduct levels and DNA 'repair' in I are caused by remaining unbound cisplatin in the
sample tubes, which can form DNA adducts ex vivo. The same results in vivo can be anticipated when
carboplatin is used.
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cis-Diamminedichloroplatinum II (cisplatin) is one of the
most potent anti-cancer agents with substantial clinical
activity against testicular cancer, ovarian cancer, head and
neck (H/N) cancer and other tumours (Loehrer and Einhorn.
1984; Reed et al., 1987). The anti-tumour activity of cisplatin
correlates with its interaction with DNA, resulting in a
limited number of inter- and intrastrand cross-links
('adducts') (Fichtinger-Schepman et al., 1990). In previous
studies wide inter-patient variation was established in the
DNA adduct kinetics in white blood cells (WBCs), which was
monitored with different enzyme-linked immunosorbent
assays (ELISAs) as well as with atomic spectroscopy (AAS)
(Reed et al., 1987a, 1988a, 1990; Fichtinger-Schepman et al..
1987, 1989a,b; Parker et al., 1991). The DNA adduct levels in
WBCs correlated with the clinical response in testicular,
ovarian and other cancer patients who were treated with
cisplatin, however substantial overlap in DNA adduct levels
was observed between responding and non-responding patients
(Reed et al., 1987, 1988a, 1993). It is important to realise that
quantitation of the DNA-adduct kinetics with different pub-
lished ELISA and AAS methods (Fichtinger-Schepman et al.,
1987, 1990; Reed et al., 1987a,b 1988a,b; Parker et al., 1991;
Poirier et al., 1993) and different sample preparation techni-
ques (Reed et al., 1987; Fichtinger-Schepman et al., 1987,
1990) resulted in > 10-fold differences in the DNA adduct
levels and shape of the DNA adduct-time curve in patients
treated with the same dose range of cisplatin. Hence cross-
validation of the published methods is very much needed.
We monitored the DNA adduct kinetics in WBCs from
patients who were treated with six weekly courses of cis-
platin. In the first group of patients we applied the protocol
for sample preparation which is described by Fichtinger-
Schepman et al. (1987, 1990) and which is also applied in
other ongoing studies. During the study we modified the
sample preparation procedure because we suspected that
application of the previously published method resulted in
overestimation of the DNA adduct levels shortly post-
infusion and of the DNA repair. We describe the two pro-
cedures and the influence on the quantitation of the DNA
adduct levels in vivo. We measured the DNA adduct-time
curve in WBCs from patients to determine the time point at
which the DNA adduct level reaches its maximal value.
Furthermore, we simulated the two sample preparation pro-
cedures in vitro using cisplatin as well as carboplatin as
model substrates to identify clearly the mechanism behind the
difference in the two assays.
Patient seleton, materials and methods
Patient selection and treatment schedule
All patients gave informed consent according to local
regulatory requirements. Eligibility for the clinical study
required a pathologically confirmed mesothelioma, mela-
noma, non-small-cell lung cancer, colon cancer, adenocar-
cinoma of unknown primary or H/N cancer. The perfor-
mance status had to be < 1 on the WHO scale and life
expectancy >s 3 months. Each patient had a complete
medical history taken and underwent a physical examination,
complete blood count, platelet count and serum tests. All
patients had adequate renal and liver function, i.e. serum
creatinine <120pmoll ' (1.4mgdl') and total bilirubin
<25pmoll-' (I.5mgdl-'), WBCs >4.0x lOl-' and plate-
let count > 100 x 109 1-'. Additional pretreatment investiga-
tions included an audiogram and a neurological examina-
tion.
H N cancer patients received six weekly courses of 80 mg
m- cisplatin. Patients with colon cancer received 75 mg -2
cisplatin im combination with oral VP16 (50 mg on days
- 15 and 29-43) and all other patients 70 mg m-2 cisplatin
in six weekly courses on days 1, 8, 15. 29, 36 and 43 in
combination with oral VP16. Cisplatin was dissolved in a 3%
sodium chloride solution and administered as a 3 h infusion
with pre- and post-hydration.
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In all patients samples of 20 ml of hepanrnised blood were
drawn during the first, third and sixth course: before cisplatin
infusion (baseline), after the end of the infusion and 15 h
after the end of the infusion. In the first group of 21 patients
(I) the second blood sample was taken at the end of the
infusion, whereas in the second group of 32 patients (II) the
sample was taken 60 min after the end of the infusion.
The whole-blood samples collected in group I were frozen
immediately at -80'C until analysis. The whole-blood
samples which were drawn from patients in group II were
centrifuged immediately for collection of the WBC.
In 7 of the 32 patients in group II, more blood samples
were collected for measurement of the DNA adduct levels.
The sampling times in these patients were at baseline and at
0, 1, 2, 5 and 15h after the end of the 3h infusion of
cisplatin.
Chemicals
Platin (Pt) standard solution (500 p.p.m.) and ammonium
chloride were obtained from Baker (Deventer, The Nether-
lands), DNAse I (EC 3.1.21.1) and RNAse (EC 3.1.27.5)
from Sigma (St Louis MO, USA). proteinase K and caesium
chloride from Merck (Darmstadt, Germany) and sodium
dodecyl sulphate (SDS) from Brunschwig (Amsterdam, The
Netherlands); all other chemicals were from Baker and were
of analytical grade or higher.
Instruments
A flameless Perkin-Elmer Model 3030B atomic spectrometer
was equipped with an AS60 autosampler and HGA600 con-
troller system (Uberlingen. Germany). The UV spectrophoto-
meter was a Beckman DU62 (Fullerton. CA. USA).
Determination oftotal and unboundplatinum in plasma and
DNA adducts in WBCs
Total and unbound platinum and DNA adduct levels were
analysed by AAS according to the method of Reed et al.
(1988b) with modifications which have been described pre-
viously (Ma et al.. 1994a). The DNA was quantitated by UV
spectrophotometrv at 260nm (Kirby. 1968).
Collection of WBCsfromfreshly drawn hole-blood samples
Immediately after collection of a volume of 20 ml of whole
blood from a patient. the sample was centrifuged for 5 min at
4'C and 1500g. The buffy coat of WBCs was taken with a
glass pipette and transferred to a 50 ml plastic tube (Greiner.
type 210261, Alphen. Rijn. The Netherlands). Ice-cold phos-
phate-buffered saline (PBS) was added to a final volume of
10ml. Remaining red blood cells were lysed by addition of
30 ml of a buffer (0.83% ammonium chloride. 0.1% potas-
sium bicarbonate, 1 mM EDTA). The mixture was shaken
gently and put on iced water for 10min afterwards. After
centrifugation (5 min at 4°C and 1500g) the WBCs were
collected and washed with PBS and a Tris-EDTA buffer
(10 nM Tris, 2 mM EDTA. pH 7.35). The WBCs were resus-
pended in 9 ml of the Tris-EDTA buffer and stored at
- 80C. The DNA was isolated and analysed within 2
months. The DNA was isolated according to a previoulsy
published method (Miller et al.. 1988) with minor
modifications. Briefly, after thawing the sample 0.9 ml of
ammonium bicarbonate (1.1 M) was added. The cell lysates
were digested overnight at 42°C with 0.45 ml of 2000 SDS
and 0.6ml of a 10 mg ml-' proteinase K solution. After the
digestion was complete. 3 ml of saturated sodium chloride
(6 M) was added to each tube and the tube shaken vigorously
for 15 s, followed by centrifugation at 2500 r.p.m. for 15 min.
The precipitated protein pellet was left at the bottom of the
tube and the supernatant containing the DNA was transfer-
red to another 50 ml polypropylene tube. Exactly two
volumes of room temperature absolute ethanol was added
Modolo for measurement of plainumDNA adducts in WBCs
J Ma et al M
513
and the tubes inverted several times until the DNA
precipitated. The precipitated DNA strands were removed
with a glass pipette. washed twice with 70% ethanol and
subsequently dissolved in a Tns-EDTA buffer (10mM Tn's-
HCl. 0.2 mM disodium EDTA. pH 7.35). Before quantitatimg
the DNA. it was allowed to dissolve overnight at room
temperature.
Collection of WBCsfromfrozen whole bloodsamples
This method is described by Fichtinger-Schepman et al.
(1987). Briefly: two portions of 10 ml of frozen whole blood
are thawed and a volume of 30 ml of the lysis buffer is added
to each of the portions. The rest of the procedure is the same
as outlined above.
In vitro simulation ofthe two samplepreparation methods
A volume of 120 ml of whole blood was taken from four
healthy volunteers. The whole blood was incubated with
cisplatin (approximately 10 jig ml-1) at 37C in a humidified
atmosphere of 5% carbon dioxide in air. At 0 (i.e. no incuba-
tion after addition of cisplatin). 1. 4 and 24 h after start of
the incubation 30 ml of blood was taken and divided into
two portions. In one portion the WBCs were collected and
frozen immediately as described above. The second whole-
blood portion was frozem immediately at - 80'C. On a
second occasion a volume of 30 ml of whole blood was
collected from the same volunteers and incubated with cisp-
latin (same concentration of 10 gg ml-'). After 0 h of incuba-
tion the sample was divided into two portions: one for
immediate collection of WBCs before storage at - 80'C and
the other for immediate storage at - 80'C. These samples
were stored at 80'C for only 20mn then thawed and pro-
cessed immediately afterwards. All other samples were stored
at - 80'C for 2 weeks. Subsequently. the WBCs were col-
lected as outlined above. The DNA adduct levels of these
samples were measured on the same day.
In another experiment a volume of 120 ml was collected
from the four volunteers for the incubation experiment with
carboplatin. The incubation concentration was 200tig ml-'.
The incubation conditions were the same as in the experi-
ment with cisplatin. The storage of duplicate samples for
only 20 min at - 80'C was not repeated with carboplatin.
To study the influence of addition of RNAse on the DNA
yield and DNA adduct level, a separate experiment was
carried out. A volume of 20 ml of heparinised whole blood
was drawn from four other subjects. The WBCs were col-
lected immediately and the DNA isolated as outlined. The
DNA was dissolved in a volume of 2 ml of a Tris-EDTA
buffer (10 nmol Tnrs. 2 mmol EDTA. pH 7.35) and divided
into two equal portions. RNAse, which was heated before
use for 5 min at 80'C. was added to one of the portions to a
final concentration of 100 yig ml-' and incubated for 2 h at
37C. The other portion served as control. After 2 h the
DNA was isolated again as outlined by addition of 0.33 ml
of saturated sodium chlonrde (6 M) and subsequently
precipitated with absolute ethanol. The DNA content and
the DNA adduct levels were compared with the control
samples. Each experiment was carred out using four samples
in duplicate.
Statistical analysis
The unpaired Student t-test was used to descnrbe differences
between the DNA adduct levels in vivo in patient groups I
and II. The paired Student t-test was used to describe
differences between the DNA adduct levels in vitro. The
paired Student t-test was also used to describe differences
between the DNA adduct levels in vivo measured at the end
of the infusion of cisplatin and at 1 h post infusion in the
outlined group of seven patients.Methodoloy for measureneu of platinum- M add..s in WCs
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Results
Patients and treatment
The 21 patients of group I received in the first course a dose
of 1665 mg m-- (mean ± s.d. = 74.0± 4.6 mg m2) and a
total dose of 2610 mg of cisplatin (141 ± 16 mg) and the 32
patients of group II 2355 mg m~2 (73.6 ± 4.8 mg m'2) and a
total dose of 4318 mg (135 ± 21 mg) (I and II not
significantly different). Seven patients in group I and ten in
group II had H N cancer and received 80 mg m-2 cisplatin.
Three patients in group I and 1 in group II received 75 mg
m 2 cisplatin. All others received 70 mg m2 cisplatin. No
significant differences in age and gender distribution or in
renal function and plasma protein level were observed
between the two groups of patients.
DNA adduct levels in the two groups ofpatients
The DNA adduct levels at the three time points during the
three observed courses are given in Figure 1. The maximal
adduct level (A.,,,) after the end of the infusion is
significantly higher in group I than in group II. The A,,
values of the first course were in group I 2.48 ± 1.14 and in
group 11 1.28 ± 0.40 pg Pt ytg-' DNA (P<0.0001). In addi-
tion. the coefficient of vanration of A,,. in group I of 46%
was much higher than of A,,,. in group II, which was 32%.
This was consistent in all measured courses. The baseline
levels of all courses were not significantly different between
groups I and II. The levels at 15 h post infusion were higher
in group I during the first (P = 0.04) and sixth course
(P = 0.05) and not significantly different during the third
course (P> 0.3) (Table I). In group I the decrease in DNA
adduct level between the end of the infusion and 15 h post
infusion of 40% ± 29% was significantly greater than in
group II, in which it was 18% ± 29% (P = 0.009). This was
consistent in all measured courses (Table I).
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Figure 1 DNA adduct levels in WBCs during courses 1, 3 and 6
in two groups of patients treated with weekly cisplatin. 0, WBCs
were collected after thawing frozen whole-blood samples; 0,
WBCs were collected immediately after collection of whole-blood
samples from the patients. Time points were baseline, end of 3 h
infusion (group I) and I h post infusion (group II) and 15 h post
infusion. **P<0.0001. *PS)0.05. NS= not significant.
DNA adduct-tune curve in seven ofthe patients in group II
The results of measurement of the DNA adduct-time curves
are shown in Figure 2. The DNA adduct level at the end of
the infusion was 1.01 ±0.29 pg PtiLg- DNA (n = 7) and at
h post infusion was 1.40 ± 0.25 pg Pt;g-' DNA (n = 7,
P = 0.013). In all patients the DNA adduct level at 1 h post
infusion was higher than at the end of the infusion.
Difference in DNA adduct levels in vitro in WBCs in the two
sample preparation methods
Application of the two sample preparation methods resulted
in significantly different levels of DNA adducts after 0, 1 and
4 h of incubation with cisplatin (Figure 3). The DNA adduct
levels in the WBCs which were collected after thawing frozen
whole-blood samples were higher than in the WBCs which
were collected immediately after blood sample collection. The
DNA adduct level at 0 h after start of the incubation was
494% higher (P<0.0001), at 1 h was 110% higher (P<
0.0001), at 4h 19% (P=0.02) and at 24h only 6% (not
significant). The DNA adduct levels in the samples which
were stored at - 80C for only 20 min were not significantly
different from the samples which were stored for 2 weeks at
-80°C.
After incubation with carboplatin, the DNA adduct levels
in WBCs collected after thawing the frozen whole-blood
sample were significantly higher at 0, 1, 4 and 24 h of incuba-
tion compared with the freshly collected WBCs (Figure 4). At
Oh the DNA adduct level was 335% higher (P =0.001), at
1 h 168% (P= 0.002), at 4h 121% (P= 0.008) and at 24h
11% (P = 0.03) higher than in the freshly isolated WBCs.
DNA content andpurity ofthe two smnple preparation
methods
The DNA content of the samples of the freshly prepared
WBCs was 186.8 ± 29.9gg l0ml-' of whole blood. The
DNA content of the samples of the WBCs which were col-
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Figrme 2 DNA adduct-time curves obtained in seven patients
from group II treated with a dose of cisplatin of 70-80 mg m2.
WBCs were isolated immediately after collection of the whole-
blood sample.
Table I DNA adduct levels in WBCs from patients treated with six weekly courses of cisplatin
DNA adct level (pg Ptrpg-' DNA) DNA 'repair'
Baseline A., Ap5 (%)
Course I II P I P I II P I II P
I 0 0 2.48 1.14 1.28 0.40 <0.0001 1.37 0.61 1.05 0.48 0.04 40 29 18 29 0.009
3 0.78±0.55 0.52±0.42 NS 3.11 ± 1.32 1.84±0.75 0.002 1.95± 1.19 1.64±0.65 NS 39±28 16±22 0.02
6 0.99 ± 0.78 0.61 ± 0.40 NS 4.18 ± 1.29 1.64 0.50 <0.0001 1.75 ± 0.85 1.16 0.44 0.05 60 24 37 ± 25 0.02
The DNA adduct time points were: baseline, 0 min (group I) or 60 min (group II) post infusion (A,) and 15 h post infusion (A15). Group I
consisted of 21 patients and the DNA adduct levels were determined in WBCs which were collected after thawing a frozen whole-blood sample.
Group II consisted of 32 patients and the WBCs were collected immediately after blood sample collection. NS. not significant. DNA 'repair'
(%) is defined as the relative difference between A,,, and A15 [(A,,, - A15) x 100,A.J.lected after thawing the frozen sample was 159.2 ± 56.9
,Lg 10 ml-' whole blood (not significantly different). The UV
ratio 2601280 nm was consistently 1.9-2.0 in both methods.
The DNA content of the four samples in duplicate which
were treated with RNAse was 214 ± 29 and in the control
samples 219 ± 29;tg 10 ml ' whole blood (not significant).
The DNA adduct levels were 7.28 ± 1.10 after treatment with
RNAse and 7.30 ± 0.66 pg Pt g-' DNA in the control sam-
ples (not significantly different).
Concentration-time profiles oftotal and unboundplatinum in
vitro
The concentration-time profiles of total and unbound plati-
num in the in vitro experiment after incubation of cisplatin
and carboplatin are shown in Figure 5 and 6. The concentra-
tion of total platinum in both experiments is almost constant.
The concentration of unbound platinum after incubation of
cisplatin decreases with a half-life of 1.0 h. After 1 h the
concentration of unbound platinum in the incubation tube
was 6.13±0.37 gml', after 4h 0.75 ±0.08 and after 24h
0.48 ± 0.07 iLg ml- '. After incubation of carboplatin the
unbound platinum concentration decreased much more slow-
ly. The half-life in vitro was approximately 24 h. After 24 h of
incubation the concentration of unbound carboplatin was
54% of the starting level.
Cisplatin-DNA adduct formation and repair has been
measured in clinical and preclinical studies in order to cor-
relate the kinetics of DNA adduct formation and repair to
the tumour response (Reed et al., 1987, 1988a, 1990, 1993;
Fichtinger-Schepman et al., 1989a, 1990; Parker et al., 1991;
Poirier et al., 1993). In clinical trials DNA adduct kinetics
has been measured in WBCs because of the limited access to
tumour tissue. The mean level of DNA adduct formation in
responding patients was significantly higher than in non-
responding patients, although the range of the data showed
an almost complete overlap (Reed et al., 1987a, 1988a, 1993).
In a recently published study in patients with germ cell
tumours however, no significant positive correlation was
observed between DNA adduct formation in WBCs and
favourable clinical response (Motzer et al., 1994). Studies on
the removal of DNA adducts illustrate that the level
decreases more than 40% in the first few hours post infusion,
which was interpreted as DNA repair (Fichtinger-Schepman
et al., 1987).
We monitored the kinetics of formation and repair of
DNA adducts in WBCs of patients with solid tumours who
Metodolog formeasurem t ofplfinumDN adducts inWBCs
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were treated with six weekly courses of high-dose cisplatin of
70-80 mg m2. In the first 21 patients the DNA adduct
levels were measured in WBCs, which were collected after
thawing frozen whole-blood samples drawn at the end of the
infusion of cisplatin according to the method previously des-
cribed (Fichtinger-Schepman et al., 1987, 1990). The method
of WBC collection was modified because we suspected an
overestimation of the DNA adduct levels shortly post
infusion and an overestimation of the DNA repair. In addi-
tion, we wanted to determine the time point after infusion of
cisplatin at which the DNA adduct level in WBCs is at its
maximum value. In the modified procedure WBC& were iso-
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Figue 4 DNA adduct levels in WBCs from four healthy sub-
jects after 0, 1, 4 and 24 h incubation of whole blood with
carboplatin in vitro. Open bar: WBCs were coBlected immediately
after the incubation period. Closed bar1 The whole-blood samples
were frozen immediately post incubation and the WBCs were
collected after thawing the samples.
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Figre 3 DNA adduct levels in WBCs from four healthy sub-
jects after 0*, 0, 1. 4 and 24 h incubation of whole blood with
cisplatin in vitro. Open Bar: WBCs were isolated immediately
after the incubation period. Closed bar: The whole-blood samples
were frozen immediately post incubation and the WBCs and
DNA were collected after thawing the samples. NS = not
significant. *0 h = samples stored at - 80-C for only 20 min, all
other samples were stored for 2 weeks at - 80C.
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(0) platinum in vitro in plasma of whole blood incubated with
carboplatin at 37C (mean + s.d., n = 4).
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lated im iately after collection of the blood sample of the
patient The differences in DNA adduct levels betwen the
two methods are illustrated in Figure 1. The DNA adduct
levels immediately post infusion in the patients denoted as
group I are sgnificntly higher than in the paients of group
H. The variability in the DNA levels in group I was also
higher than in group H, which is illustated by the higher
coefficients of variation.
There was a difference in sampling time of nearly 60min
between groups I and H. Measurement of the DNA adduct
levels at 1 h post infusion in seven patients of group H
revealed that the levels were 40% higher than at the end of
the infusion. Hence, the difference in the sampling time can-
not explain the observed difference. In addition, it seems to
be favourable to measure DNA adduct levels in WBCs at 1 h
post infusion to obtain the best estimate of the maximal
DNA adduct level. The half-life of unbound cisplatin in vivo
is approximately 30min (Vermorken et al., 1982), which
indicates that during the first hour post infusion WBCs are
still exposed to significant concentrations of active casplatin.
This appears to be the most reasonable explanation for the
increased DNA adduct levels at 1 h post infusion compared
with the level at the end of the infusion.
The difference between the DNA adduct levels groups I
and II can be explained by the presence ofunbound dsplatin
in the blood sample tube, which can form DNA adducts ex
vivo. As a consequence of the short half-life of unbound
cisplatin, the concentration of unbound splatin is almost
zero 15 h post infusion. If WBCs are isolated imediately
after collection of the blood sample, then the redistribution
of isplatin and binding to the DNA in WBCs ex vivo can be
prevented. The sharp decine in the DNA adduct level
between the end of the infusion and some time the next
morning (approximately 15 h later) has been interpreted
previously as DNA repair (Fichtinger-Schepman et al., 1987,
1990). The DNA repair in group H during the first course
was on average more than 50% lower than in the patients of
group I (Table I).
The differences between the DNA adduct levels at 15 h
post infusion in groups I and H were much smaller. The
difference was signnt during the first course, not
significant during the third and marginaLly significnt during
the sixth course. This is in line with the almost undetectable
concentration of unbound cisplatin in patients at this time
point. It cannot be excluded that unbalanced patient selec-
tion and variation in the dosage of cisplatin contributed to
the observed differences between groups I and H. The mean
and s.d. of the administered dose of csplatin in the two
treatment groups were not significntly different, however the
pharmacokinetics of unbound isplatin may have been
different. Variation in the pharmacokinetics may result in
differences in the DNA adduct levels between the patient
groups, because in a previous study a linear relationship was
observed between the exposure to unbound cisplatin and the
level of the DNA adduct formation in WBCs (Ma et al.,
1994b).
The two methods of WBC collection were simulated in
vitro to exclude further the contribution of differences in the
sampling and pharmacokinetics of cisplatin. The DNA
adduct level in WBCs ofwhole blood incubated in vitro with
cisplatin was 494% higher after 0 h ofincubation and 110%
higher after 1 h ofincubation (Figure 3). After 4h the differ-
ence was reduced to 19%, whereas after 24 h the difference
was only 6% and no longer significant. The concentration-
time curve of asplatin in vitro (Figure 5) illustrates that at 0
and 1 h after start of the incubation high levels of unbound
cisplatin are present in the incubation tube, whereas the
concentration is much lower at 4 and 24 h after start of the
incubation. This experiment illustrates that in WBCs DNA
adduct formation with rmaining unbound cisplatin in the
blood sample collection tube will take place. Even immediate
storage of the sample tube at -80-C did not prevent DNA
adduct formation ex vivo. The combination of high DNA
adduct levels shortly post infusion and low levels 15 h later
may therefore be erroneously interpreted as a high level of
DNA repair. The DNA adduct levels in the WBCs stored for
only 20 min at - 80C were not different from the levels after
storage of the WBCs for 2 weeks at -80-C. This indicates
that formation of DNA adducts proceeds during thawing
and work-up of the sample and not during the storage at
- 80-C. We speculate that the high level of DNA adduct
formation during the thawing and work-up, in the presence
of unbound cisplatin, is caused by an increase in the
permeability of the cell membranes of the WBCs. This may
result in increased intracellular concentrations of cisplatin
and DNA adduct formation.
No significnt differences were found in the DNA content
of the samples obtained with the two different sample
preparation methods. The UV ratio indicated no protein
contamination in both methods. The results of the experi-
ment in which RNAse was added before quantitation of
DNA and DNA adduct levels illustrate that RNA con-
tamination is likely to be negligible.
Carboplatin was used as a second substrate, because DNA
adduct formation in WBCs has also been studied extensively
in patients treated with carboplatin. In addition, assesment
of the same relationship between DNA adduct formation ex
vivo and the presence of unbound carboplatin in the sample
tubes confirms the mechanism of the described phenomenon.
The DNA adduct levels in vitro after incubation with carbo-
platin are significntly higher even after 24 h of incubation.
The disappearance half-life of carboplatin in vitro, however,
is much longer than of cisplatin, and after 24 h the concen-
tration of unbound carboplatin is still 54% of the starting
level. This explains the significnt difference in the DNA
adduct levels between the two sample handling methods at
this late time point.
WBC coliection from frozen whole-blood samples is applied
in ongoing clnical studies, for example in one crried out
within the framework ofthe World Health Organization. The
aim of these studies is to establish the relationship between
DNA adduct kinetics and the tumour response in patients
with solid tumours. It should be realise that the WBC
collection method used in these studies will result in overes-
timation of DNA adduct levels and DNA 'repair'.
hi addition, WBCs should be collected imm atey after
the blood sample has been drawn to further reduce variation
in the DNA adduct measurement. Standardisation of this
procedure is recommended. It is of interest to reveal any
contribution of method variation to the inter-patient
variability in DNA adduct levels in WBCs. It may reduce the
observed overlap in DNA adduct levels between responders
and non-responders to isplatin chemotherapy. Also, after
administration of carboplatin, WBCs should be isolated
immdi;ately if the blood sample is drawn during the time
Period that unbound carboplatin in plasma can be antici-
pated.
We have quantitated DNA adduct levels in WBCs from 43
patets with various types of solid tumours treated with
cisplain at a dose of 70-80 mg m-2. Preliminary results
indicate that the coefficient of variation of the DNA adduct
levels at 1 h post infusion is only 27% with a less than 6-fold
range (Ma et al., 1994b). In our opinion, use of the outlined
optimised metho reduces the contribution of assay variation
to the inter-patient variability in DNA adduct levels in
WBCs.Mehodolo formeasurement o platinumDNAadducts inWBCs
J Ma et al
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